GB202106014D0 - Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients - Google Patents

Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Info

Publication number
GB202106014D0
GB202106014D0 GBGB2106014.0A GB202106014A GB202106014D0 GB 202106014 D0 GB202106014 D0 GB 202106014D0 GB 202106014 A GB202106014 A GB 202106014A GB 202106014 D0 GB202106014 D0 GB 202106014D0
Authority
GB
United Kingdom
Prior art keywords
cov
sars
beta
infected patients
improve outcome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2106014.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synairgen Research Ltd
Original Assignee
Synairgen Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synairgen Research Ltd filed Critical Synairgen Research Ltd
Priority to GBGB2106014.0A priority Critical patent/GB202106014D0/en
Publication of GB202106014D0 publication Critical patent/GB202106014D0/en
Priority to PCT/GB2021/051853 priority patent/WO2022018422A1/en
Priority to CN202180061898.1A priority patent/CN116472054A/en
Priority to KR1020237005777A priority patent/KR20230041097A/en
Priority to JP2023504184A priority patent/JP2023535710A/en
Priority to EP21749262.8A priority patent/EP4181944A1/en
Priority to US18/016,964 priority patent/US20230338475A1/en
Ceased legal-status Critical Current

Links

GBGB2106014.0A 2020-07-20 2021-04-27 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients Ceased GB202106014D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2106014.0A GB202106014D0 (en) 2021-04-27 2021-04-27 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
PCT/GB2021/051853 WO2022018422A1 (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
CN202180061898.1A CN116472054A (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving prognosis of SARS-CoV-2 infected patient
KR1020237005777A KR20230041097A (en) 2020-07-20 2021-07-19 Inhaled interferon-beta to improve outcomes in patients with SARS-CoV-2 infection
JP2023504184A JP2023535710A (en) 2020-07-20 2021-07-19 Inhaled interferon-beta to improve outcomes in patients infected with SARS-CoV-2
EP21749262.8A EP4181944A1 (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
US18/016,964 US20230338475A1 (en) 2020-07-20 2021-07-19 USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2106014.0A GB202106014D0 (en) 2021-04-27 2021-04-27 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Publications (1)

Publication Number Publication Date
GB202106014D0 true GB202106014D0 (en) 2021-06-09

Family

ID=76193461

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2106014.0A Ceased GB202106014D0 (en) 2020-07-20 2021-04-27 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Country Status (2)

Country Link
CN (1) CN116472054A (en)
GB (1) GB202106014D0 (en)

Also Published As

Publication number Publication date
CN116472054A (en) 2023-07-21

Similar Documents

Publication Publication Date Title
HK1208910A1 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective gpc3 gpc3
GEP20166455B (en) Methods of administering pirfenidone therapy
IN2012DN06616A (en)
MY173215A (en) Acetylcysteine compositions and methods of use thereof
NZ599246A (en) Pirfenidone therapy and inducers of cytochrome p450
MX2017012982A (en) Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes.
NZ599511A (en) Recombinant human cc10 protein for treatment of influenza
MX2020011107A (en) Glycosidase regimen for treatment of infectious disease.
EP4112050A4 (en) Use of nucleoside compound in treatment of coronavirus infectious diseases
BR112014007580A2 (en) medical intervention device and method of manufacture
GB202302767D0 (en) Improvements in or relating to patient care
GB202106014D0 (en) Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB202011284D0 (en) Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB202011216D0 (en) Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients
MX2019002657A (en) Combinations with a backbone-cyclized peptide.
MX2019002894A (en) Combinations with a backbone-cyclized peptide.
IL308992A (en) Treatment of cancer in patients with soluble fr-alpha
RU2013129824A (en) NEW TREATMENT OF HEPATITIS C VIRUS INFECTION
MX2022007908A (en) Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
GB202100322D0 (en) Artificial up-regulation of EGR1 protein in COVID19 infected lung tissues as a therapeutic treatment
GB202303291D0 (en) Medicament and medicament combination for use in the treatment of infectious disease
ZA202201362B (en) Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumor
陈可冀 New findings validate an ancient technique: how massage affects the biochemistry of inflammation
UA47947U (en) Method for treating chronic viral hepatitis b and c in children

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)